Company

Products

Sponsors

Resources

FDA Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency

SHARE

FDA plays a critical role in protecting the United States from threats such as emerging infectious diseases, including the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to providing timely guidance to support response efforts to this pandemic.

FDA is issuing this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity for the duration of the COVID-19 public health emergency. The appendix to this guidance further explains those general considerations by providing answers to questions that the Agency has received about conducting clinical trials during the COVID-19 public health emergency.

You can access this guidance by clicking here: FDA Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency